To receive all of Ikonisys’ financial information in real time, send a request by email to [email protected]. Your registration will be immediate.
Mario Crovetto, CEO of Ikonisys, said: “This operation is motivated by our desire to preserve our financial flexibility, in addition to the other sources of financing available, in order to pursue the development of the company with efficiency and agility. This development will mainly involve the acceleration of the commercial strategy in the United States and Europe, through additional marketing investments, as well as the continued development of the Ikoniscope20 platform, in particular through the detection of circulating tumor cells (CTC ) and the integration of artificial intelligence (AI). »